Novo Nordisk's (NVO) pending acquisition of Catalent (CTLT) is facing a roadblock after US consumer groups and two large labor unions urged regulators to block the deal, citing competition concerns.
In a letter to the US Federal Trade Commission on Thursday, the US Public Interest Research Group, Service Employees International Union, and other groups said the deal threatens competition in obesity drugs and other gene therapies as Novo would have the ability to prevent rival manufacturers from obtaining Catalent services, which will ultimately reduce patient access to treatments.
Novo Nordisk and Catalent did not immediately respond to MTNewswires' request for comment.
Price: 117.31, Change: -0.91, Percent Change: -0.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。